Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma

Michio Ozeki, Akifumi Nozawa, Kaori Kanda, Tomohiro Hori, Akihito Nagano, Akira Shimada, Tatsuhiko Miyazaki, Toshiyuki Fukao

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pseudomyogenic hemangioendothelioma (PMH) is a recently described vascular neoplasm that occurs most commonly in the soft tissue of the distal extremities of young adults. Metastatic PMH can be fatal and there are no effective medications. We describe a case of a 15-year-old boy with metastatic PMH, who responded to treatment with everolimus, a mammalian target of rapamycin inhibitor. Immunohistochemistry showed that mammalian target of rapamycin was expressed in PMH biopsy specimens, which may explain the reduction in PMH tumor size following treatment.

Original languageEnglish
Pages (from-to)e328-e331
JournalJournal of Pediatric Hematology/Oncology
Volume39
Issue number6
DOIs
Publication statusPublished - 2017

Keywords

  • kaposiform hemangioendothelioma (KHE)
  • mammalian target of rapamycin (mTOR) inhibitor
  • phosphoinositide-3-kinase (PI3K)
  • soft tissue tumor
  • vascular tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma'. Together they form a unique fingerprint.

  • Cite this

    Ozeki, M., Nozawa, A., Kanda, K., Hori, T., Nagano, A., Shimada, A., Miyazaki, T., & Fukao, T. (2017). Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma. Journal of Pediatric Hematology/Oncology, 39(6), e328-e331. https://doi.org/10.1097/MPH.0000000000000778